Evidence map›Paper›PMID 39810270›Full record

ArticleTropical medicine and health2025

Sero-molecular prevalence of toxoplasmosis in hemodialysis and peritoneal dialysis patients in Markazi Province, Iran.

Hossein Sarmadian, Mana Shojapour, Fereshteh Chegeni, Mohammad Amin Tabatabaiefar, Farshid Haghverdi, Roham Sarmadian, Reza Ghasemikhah

Abstract read
In one paragraph

Article in Tropical medicine and health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hossein SarmadianDepartment of Infectious Disease, School of Medicine, Arak University of Medical Sciences, Arak, Iran.
Mana ShojapourMolecular and Medicine Research Center, Arak University of Medical Sciences, Arak, Iran.
Fereshteh ChegeniStudents Research Committee, Arak University of Medical Sciences, Arak, Iran.
Mohammad Amin TabatabaiefarDepartment of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Farshid HaghverdiNephrology Department of Internal Medicine, School of Medicine, Amiralmomenin Hospital Arak University of Medical Sciences, Arak, Iran.
Roham SarmadianInfectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran.
Reza GhasemikhahInfectious Diseases Research Center, Arak University of Medical Sciences, Arak, Iran. ghasemikhah@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInfectious diseases, particularly parasitic infections such as toxoplasmosis, contribute significantly to the morbidity and mortality of hemodialysis patients. Toxoplasma gondii infection poses serious risks, especially to immunocompromised individuals. This study aimed to assess the prevalence of latent toxoplasmosis in dialysis patients in Markazi Province, Iran.

methodsA total of 181 patients (168 hemodialysis and 13 peritoneal dialysis) were included in this cross-sectional study. Blood samples were collected and tested for anti-Toxoplasma IgG and IgM antibodies using ELISA, while PCR was used to detect T. gondii DNA. Data were analyzed using SPSS, with P < 0.05 considered significant.

resultsOut of 181 patients, 123 (67.95%) were seropositive for IgG antibodies, with the highest prevalence in those aged over 60 years. No cases tested positive for IgM antibodies or T. gondii DNA. Age was significantly associated with higher seroprevalence (P < 0.05), but there were no significant differences regarding gender, dialysis type, or duration of dialysis.

conclusionThe high prevalence of latent toxoplasmosis in dialysis patients underscores the need for regular screening to prevent serious complications. Given the limitations of serological tests, molecular diagnostics like PCR should be considered for better detection in immunocompromised patients.

Indexed as

ELISAHemodialysisPCRToxoplasmosis

Identifiers

PMID39810270
PMCPMC11730123

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.